Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32360444    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32360444 :   free
PDF vom PMID32360444  :  Publisher

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP) #MMPMID32360444
  • Bassetti M; Giacobbe DR; Aliberti S; Barisione E; Centanni S; De Rosa FG; Di Marco F; Gori A; Granata G; Mikulska M; Petrosillo N; Richeldi L; Santus P; Tascini C; Vena A; Viale P; Blasi F
  • Clin Microbiol Infect 2020[Jul]; 26 (7): 880-894 PMID32360444show ga
  • BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure. At the present time the absolute number of severe cases requiring ventilator support is reaching or even surpassing the intensive care unit bed capacity in the most affected regions and countries. OBJECTIVES: To narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and frontline opinions and to provide balanced answers to pressing clinical questions. SOURCES: Inductive PubMed search for publications relevant to the topic. CONTENT: The available literature and the authors' frontline-based opinion are summarized in brief narrative answers to selected clinical questions, with a conclusive statement provided for each answer. IMPLICATIONS: Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, as they are not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled onto randomized clinical trials. Access to well-designed randomized controlled trials should be expanded as much as possible because it is the most secure way to change for the better our approach to COVID-19 patients.
  • |Anti-Inflammatory Agents/*therapeutic use[MESH]
  • |Antiviral Agents/*therapeutic use[MESH]
  • |Betacoronavirus/*drug effects[MESH]
  • |Coronavirus Infections/*drug therapy/epidemiology[MESH]
  • |Humans[MESH]
  • |Intensive Care Units/statistics & numerical data[MESH]
  • |Italy/epidemiology[MESH]
  • |Lung Diseases/drug therapy/pathology/virology[MESH]
  • |Off-Label Use/*ethics[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*drug therapy/epidemiology[MESH]
  • |Respiration, Artificial/methods[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    880 7.26 2020